Further investigation of epigenetic modifiers in combination with contemporary 3rd generation EGFR TKI osimertinib in EGFR-mutant NSCLC are needed to determine the utility of epigenetic drugs in the context of acquired resistance to EGFR targeted therapeutics that is associated with phenotypic transformation. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.